Who are Induction Paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Colchicine Pill, NK105, Carboplatin plus Paclitaxel, Docetaxel, Cisplatin, Cisplatin and Docetaxel, similar placebo to mebendazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/induction-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Induction Paclitaxel — Competitive Intelligence Brief

Induction Paclitaxel (Induction Paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane. Area: Oncology.

phase 2 Taxane Beta-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Induction Paclitaxel (Induction Paclitaxel) — Radiation Therapy Oncology Group. Inhibits microtubule assembly by binding to tubulin

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Induction Paclitaxel TARGET	Induction Paclitaxel	Radiation Therapy Oncology Group	phase 2	Taxane	Beta-tubulin
Colchicine Pill	Colchicine Pill	Brigham and Women's Hospital	marketed	Microtubule inhibitor / Anti-inflammatory agent	Beta-tubulin
NK105	NK105	Nippon Kayaku Co., Ltd.	phase 3	Microtubule inhibitor	Beta-tubulin
Carboplatin plus Paclitaxel	Carboplatin plus Paclitaxel	The University of Hong Kong	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); beta-tubulin (paclitaxel)
Docetaxel, Cisplatin	Docetaxel, Cisplatin	Samsung Medical Center	phase 3	Chemotherapy combination (taxane + platinum agent)	Beta-tubulin (docetaxel); DNA (cisplatin)
Cisplatin and Docetaxel	Cisplatin and Docetaxel	Swiss Cancer Institute	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (cisplatin); beta-tubulin (docetaxel)
similar placebo to mebendazole	similar placebo to mebendazole	Swiss Tropical & Public Health Institute	phase 3	Anthelmintic	Beta-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane class)

Sanofi · 3 drugs in this class
Akeso · 1 drug in this class
Fourth Affiliated Hospital of Guangxi Medical University · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Central European Society for Anticancer Drug Research · 1 drug in this class
Chengdu Kanghong Biotech Co., Ltd. · 1 drug in this class
Biotech Pharmaceutical Co., Ltd. · 1 drug in this class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 drug in this class
Jina Pharmaceuticals Inc. · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Induction Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/induction-paclitaxel. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab